Despoina G. Dimopoulou

Suggest Changes
Learn More
BACKGROUND Low disease activity is a validated target of current systemic lupus erythematosus (SLE) therapy. The aim of this study was to assess the ability of belimumab to achieve low disease(More)
  • 1